University of Nottingham
The University of Nottingham is a prominent institution known for its comprehensive and research-led approach to education. With a strong commitment to internationalization, it attracts top students and staff globally, ensuring a rich academic experience. The university operates Nottingham University Business School, which has campuses in the UK, China, and Malaysia, and is recognized for its influential research in areas such as banking, finance, entrepreneurship, and business sustainability. The school maintains strong ties with the corporate sector and offers high-quality teaching programs that prepare students for success in an increasingly global environment. Additionally, the University manages an endowment fund that supports scholarships, research, and various academic initiatives, reinforcing its dedication to educational excellence and public service.
Cheesecake Energy is developing advanced thermal and compressed air energy systems to store energy from intermittent renewables, turning them into reliable power on-demand.
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.
One Third Stories makes learning a language as simple as reading a story, one that start in English and end in a different language by utilising their innovative Clockwork Methodology®. These are delivered as part of a monthly subscription box for parents and their kids to embark on a language learning adventure.
NuVision™ is a spin-out company from the University of Nottingham, incorporated July 2014. The company was established to commercialise high quality and affordable biotherapies for treating ‘front of the eye’ disease and trauma. Dr Andrew Hopkinson, the Principal Research Fellow in Academic Ophthalmology, Division of Clinical Neuroscience at the University of Nottingham, founded NuVision™. The business is co-owned by the founders, Dr Andrew Hopkinson (Chief Scientific Officer), Professor Harminder Dua (co-founder), the directors Mr Byran Lister (CEO) and Dr Helen Shaw (Chairman), and the University of Nottingham.
One Third Stories makes learning a language as simple as reading a story, one that start in English and end in a different language by utilising their innovative Clockwork Methodology®. These are delivered as part of a monthly subscription box for parents and their kids to embark on a language learning adventure.
Based in the United Kingdom, Monica Healthcare is developing a series of innovative wearable devices that will use wireless technologies to facilitate globally accessible obstetric services in the home and hospital. The patented technology is based on the acquisition of electro-physiological signals that can be passively detected by electrodes positioned on the maternal abdomen.
Exonate Limited is a private biotech company based in Duxford, United Kingdom, specializing in the discovery and development of small molecule drugs aimed at modulating alternative messenger RNA splicing for ophthalmological applications. Founded in 2013, the company emerged from the University of Nottingham and is focused on addressing retinal vascular diseases, particularly diabetic macular oedema (DMO) and wet age-related macular degeneration (wAMD). Exonate's lead program utilizes small molecule inhibitors that selectively target serine/threonine-protein kinase 1 to inhibit the production of pro-angiogenic vascular endothelial growth factor (VEGF) splice variants. This innovative approach aims to improve therapeutic outcomes and offers a potential alternative to current treatment methods, such as anti-VEGF injections and laser surgery. With a preclinical candidate drug already nominated, Exonate is advancing its research through regulatory toxicology and safety pharmacology studies to facilitate clinical evaluation. The company is backed by an experienced management team with expertise in medicine and drug development.
Based in the United Kingdom, Monica Healthcare is developing a series of innovative wearable devices that will use wireless technologies to facilitate globally accessible obstetric services in the home and hospital. The patented technology is based on the acquisition of electro-physiological signals that can be passively detected by electrodes positioned on the maternal abdomen.
Critical Pharmaceuticals Limited is a biotechnology company based in Nottingham, United Kingdom, that specializes in the development of biological drug products using innovative drug delivery technologies. Founded in 2002 by Professor Steve Howdle, the company focuses on non-invasive nasal delivery and sustained release formulations for proteins, peptides, and small molecules. Its proprietary technologies, CriticalSorb and CriticalMix, facilitate the nasal delivery of biologics and the manufacture of depot products that allow for infrequent injections. The company's product pipeline includes CP024, a nasal growth hormone for growth hormone deficiency; CP046, a nasal treatment for osteoporosis; and CP057, a sustained-release formulation of Bevacizumab for age-related macular degeneration, among others. However, as of July 31, 2017, Critical Pharmaceuticals Limited has entered liquidation.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.